Click to view our statement on Accessibility

Yogeeta B. Jadhav

Senior Technical Specialist – Chemistry

Back

Yogeeta B. Jadhav

Senior Technical Specialist – Chemistry

Madison 608.258.4233

Sectors

Practice Areas

Education

  • University Department of Chemical Technology, India (Ph.D., 2001)
    • Chemistry
  • Mumbai University (M.S., 1996)
    • Organic Chemistry

Dr. Yogeeta Jadhav thrives on applying her extensive knowledge of chemistry and leveraging over 15 years of patent practice experience to assist clients in protecting their inventions. Her wide-ranging experience includes preparation and prosecution of patent applications; patentability assessment; freedom-to-operate, non-infringement, and patent validity analysis; and due diligence matters spanning a broad spectrum of technologies, including pharmaceuticals, nutraceuticals, chemical processes, formulations, coatings, small molecules, cannabis, food chemistry, hair and skin care products, batteries, catalysts, pet products, and polymers. She is a member of the Firm’s Intellectual Property Department, Health Care & Life Sciences Sector, and Chemical, Biotechnology & Pharmaceutical Practice.

Prior to joining Foley, Yogeeta was a patent scientist at Sandoz India Pvt Ltd, the generic pharmaceuticals division of Novartis. She also worked as a research manager with Lupin Limited, a leading global pharmaceutical company based in Pune, India, where she assisted attorneys with respect to drafting, filing, and prosecuting patent applications; conducting infringement analysis; and evaluating new drug molecules for their patent situation, chemistry, process and technical complexity, and polymorph issues.

After completing her doctoral degree, Yogeeta was a postdoctoral fellow at Monash University in Australia, where she continued her doctoral research focused on the development of a catalytic process for the hydration of aromatic epoxides and phase transfer catalytic reactions in the organic process industry, including agrochemicals, pharmaceuticals, and perfumes, respectively. Her research has resulted in several journal publications and has been presented at national and international conferences.

Presentations and Publications

  • “Role of the Omega Phase in the Analysis and Intensification of Solid-Liquid Phase-Transfer-Catalyzed Reactions,” Jadhav, Y.; Yadav, G., Langmuir, 18 (16), 5995–6002, 2002
  • “Synthesis of 2, 4-dichlorophenoxyacetic acid: Novelties of Kinetics of Inverse Phase Transfer Catalysis,” Jadhav, Y.; Yadav, G., J. Mol Catalysis A: Chemical, 184 (1–2), 151–160, 2002
  • “Kinetics and Modeling of Liquid-Liquid Phase Transfer Catalyzed Synthesis of p-chlorophenyl acetonitrile: Role of Co-catalyst in Intensification of Rates and Selectivity,” Jadhav, Y.; Yadav, G., J Molecular Catalysis A: Chemical, 192, 41–52, 2003
  • “Cascade Engineered Phase Transfer Catalysis: A Novel Concept in Green Chemistry,” Jadhav, Y.; Yadav, G., Clean Tech. Environ. Policy, 6(1), 32–42, 2003
  • “Novelties of Solid-Liquid Phase Transfer Catalyzed Synthesis of I-isopropyl-p-chlorophenyl acetonitrile from pchlorophenyl acetonitrile,” Jadhav, Y.; Yadav, G., Organic Process Research & Development, 7(4), 588-598, 2003
  • “Novelties of Kinetics and Mechanism of Liquid-Liquid Phase Transfer Catalyzed Reduction of p-nitroanisole to p-anisidine,” Jadhav, Y.; Yadav, G.; Sengupta, S., Chem. Engg. Science, 55(12), 2681–2689, 2003
  • “Selectively Engineered Phase Transfer Catalysis in the Synthesis of Fine Chemicals: Reactions of p-chloronitrobenzene with sodium sulphide,” Jadhav, Y.; Yadav, G.; Sengupta, J. Molecular Catalysis A: Chemical, 200, 117–129, 2003

Languages

  • Hindi (fluent)
  • Marathi (native)
24 June 2024 PharmaPatents

USPTO Publishes Drug Patent and Exclusivity Study Report

The U.S. Patent and Trademark Office in conjunction with the Food and Drug Administration, and in response to January and April 2022 letters from Senator Thom Tillis, has published a report examining the time from approval of a New Drug Application until the first generic launch for 25 drug products, including consideration of patent and regulatory exclusivities.
16 May 2023 Blogs

Federal Circuit Considers Patentability of Overlapping Ranges

In UCB Inc. v. Actavis Laboratories UT Inc., the Federal Circuit affirmed the district court’s judgement of invalidity on obviousness grounds but reversed the finding of anticipation.
14 March 2023 Blogs

USPTO Discusses Duty of Disclosure and Duty of Reasonable Inquiry

On February 23, 2023, the U.S. Patent and Trademark Office held a virtual panel discussion on the duty of disclosure and duty of reasonable inquiry.
30 January 2023 Blogs

USPTO-FDA Listening Session — Voices from Patient and Patent Advocates

On January 19, 2023, the U.S. Patent and Trademark Office (USPTO) and Food and Drug Administration (FDA) held a “listening session” focusing on USPTO-FDA collaboration initiatives proposed pursuant to President Biden's Executive Order on “Promoting Competition in the American Economy” to “promote greater access to medicines for American families.”
15 May 2018 Blogs

Claim Construction Of An Enantiomeric Chemical Structure

In <EM>Sumitomo Dainippon Pharma Co. V. Emcure Pharm. Ltd</EM>., the Federal Circuit affirmed the district court’s decision that construed a chemical structure as reading on the lurasidone enantiomer that is the active ingredient of Latuda®.
23 May 2017 Blogs

CAFC Finds ANDA Infringement Despite Differences Between FDA Labeling And Claim Language

In a non-precedential decision issued in <EM>Braintree Labs., Inc. v. Breckenridge Pharmaceutical, Inc</EM>., the Federal Circuit reversed the district court’s grant of summary judgment of noninfringement in favor of Breckenridge.
View All Insights